Even though, MYCN gene amplification accounts for 50% of all high-risk neuroblastoma cases, the malignant MYCN non-amplified neuroblastomas never gain secondary gene amplifications during tumor progression or relapse, which is an uncommon feature of oncogenes in adult cancers (17). The gene discussed is MYCN; the disease is cancer.